end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableAndAccruedLiabilitiesCurrent,AccountsPayableAndOtherAccruedLiabilities,AccountsPayableAndOtherAccruedLiabilitiesCurrent,AccountsReceivableNetCurrent,AccruedIncomeTaxesCurrent,AccruedRoyaltiesCurrent,AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,AccumulatedOtherComprehensiveIncomeLossNetOfTax,AdditionalPaidInCapitalCommonStock,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AllocatedShareBasedCompensationExpense,AmortizationOfIntangibleAssets,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Assets,AssetsCurrent,AssetsNoncurrent,AvailableForSaleSecuritiesDebtSecurities,BusinessCombinationContingentConsiderationLiabilityCurrent,BusinessCombinationContingentConsiderationLiabilityNoncurrent,CashAndCashEquivalentsAtCarryingValue,CashAndCashEquivalentsAtCarryingValue,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,ComprehensiveIncomeNetOfTax,ContractWithCustomerLiability,ContractWithCustomerLiabilityCurrent,ContractWithCustomerLiabilityRevenueRecognized,DeferredCompensationShareBasedArrangementsLiabilityCurrent,DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent,DeferredIncomeTaxExpenseBenefit,DeferredIncomeTaxLiabilitiesNet,Depreciation,DepreciationAndAmortization,EarningsPerShareBasic,EarningsPerShareDiluted,EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,EmployeeRelatedLiabilitiesCurrent,FairValueLiabilitiesLevel1ToLevel2TransfersAmount,FairValueLiabilitiesLevel2ToLevel1TransfersAmount,FiniteLivedIntangibleAssetsAccumulatedAmortization,FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths,FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear,FiniteLivedIntangibleAssetsAmortizationExpenseYearFour,FiniteLivedIntangibleAssetsAmortizationExpenseYearThree,FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo,FiniteLivedIntangibleAssetsGross,FiniteLivedIntangibleAssetsNet,GeneralAndAdministrativeExpense,Goodwill,IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,IncomeTaxExpenseBenefit,IncreaseDecreaseInAccruedIncomeTaxesPayable,IncreaseDecreaseInDeferredRevenue,IncreaseDecreaseInOtherOperatingAssets,IncreaseDecreaseInOtherOperatingCapitalNet,IncreaseDecreaseInReceivables,IncreaseDecreaseInRoyaltiesPayable,IncrementalCommonSharesAttributableToConversionOfPreferredStock,IncrementalCommonSharesAttributableToShareBasedPaymentArrangements,IntangibleAssetsNetExcludingGoodwill,InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,LiabilitiesNoncurrent,LongTermDebtCurrent,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInInvestingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NetIncomeLossAvailableToCommonStockholdersBasic,NetIncomeLossAvailableToCommonStockholdersDiluted,NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1,NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1,NonoperatingIncomeExpense,OperatingExpenses,OperatingIncomeLoss,OperatingLeaseLiabilityCurrent,OperatingLeaseLiabilityNoncurrent,OperatingLeaseRightOfUseAssetAmortizationExpense,OtherAssetsCurrent,OtherAssetsNoncurrent,OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,OtherLiabilitiesNoncurrent,OtherNoncashIncomeExpense,OtherNonoperatingIncomeExpense,PaymentForContingentConsiderationLiabilityFinancingActivities,PaymentsOfFinancingCosts,PaymentsToAcquireBusinessesNetOfCashAcquired,PaymentsToAcquireEquityMethodInvestments,PaymentsToAcquireIntangibleAssets,PaymentsToAcquireInvestments,PaymentsToAcquireMarketableSecurities,PaymentsToAcquirePropertyPlantAndEquipment,PreferredStockDividendsIncomeStatementImpact,PrepaidExpenseCurrent,ProceedsFromCollectionOfLongtermLoansToRelatedParties,ProceedsFromIssuanceOfLongTermDebt,ProceedsFromIssuanceOfPreferredStockAndPreferenceStock,ProceedsFromSaleAndMaturityOfMarketableSecurities,ProceedsFromStockOptionsExercised,ProfitLoss,PropertyPlantAndEquipmentGross,PropertyPlantAndEquipmentNet,RepaymentsOfLongTermDebt,RepaymentsOfShortTermDebt,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,RevenueFromContractWithCustomerExcludingAssessedTax,RoyaltyExpense,SellingAndMarketingExpense,ShareBasedCompensation,StockholdersEquity,StockIssuedDuringPeriodValueNewIssues,StockIssuedDuringPeriodValueStockOptionsExercised,TaxesPayableCurrent,UnbilledReceivablesCurrent,WeightedAverageNumberOfDilutedSharesOutstanding,WeightedAverageNumberOfSharesOutstandingBasic,AccruedLiabilitiesCurrent,AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables,BusinessCombinationContingentConsiderationLiability,CapitalExpendituresIncurredButNotYetPaid,Cash,CashEquivalentsAtCarryingValue,CommonStockParOrStatedValuePerShare,CurrentFederalTaxExpenseBenefit,CurrentForeignTaxExpenseBenefit,CurrentIncomeTaxExpenseBenefit,DeferredFederalIncomeTaxExpenseBenefit,DeferredForeignIncomeTaxExpenseBenefit,DeferredIncomeTaxLiabilities,DeferredTaxAssetsDeferredIncome,DeferredTaxAssetsGross,DeferredTaxAssetsLiabilitiesNet,DeferredTaxAssetsNet,DeferredTaxAssetsOperatingLossCarryforwards,DeferredTaxAssetsOperatingLossCarryforwardsForeign,DeferredTaxAssetsOther,DeferredTaxAssetsValuationAllowance,DeferredTaxLiabilities,DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets,DeferredTaxLiabilitiesOther,DeferredTaxLiabilitiesOtherFiniteLivedAssets,DeferredTaxLiabilitiesPropertyPlantAndEquipment,Dividends,DividendsCash,EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate,EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount,EffectiveIncomeTaxRateReconciliationTaxSettlements,FiniteLivedIntangibleAssetsAmortizationExpenseYearFive,ForeignCurrencyTransactionGainLossBeforeTax,GoodwillAcquiredDuringPeriod,ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill,IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic,IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign,IncomeTaxesReceivable,IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance,IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate,IncomeTaxReconciliationOtherAdjustments,IncomeTaxReconciliationTaxCreditsResearch,InvestmentIncomeInterest,InvestmentInterestRate,LeaseholdImprovementsGross,LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive,LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths,LesseeOperatingLeaseLiabilityPaymentsDueYearFive,LesseeOperatingLeaseLiabilityPaymentsDueYearFour,LesseeOperatingLeaseLiabilityPaymentsDueYearThree,LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,MarketableSecurities,OperatingLeaseExpense,OperatingLeaseLiability,OperatingLeaseWeightedAverageDiscountRatePercent,PrepaidExpenseNoncurrent,ProceedsFromIssuanceOfCommonStock,ProceedsFromPaymentsForLongTermLoansForRelatedParties,ProceedsFromRepaymentsOfShortTermDebt,RestrictedCash,RestrictedInvestmentsNoncurrent,SecurityDeposit,StockholdersEquityNoteStockSplitConversionRatio1,UnrecognizedTaxBenefits,UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions,UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2020-12-31,2021-03-30,10-K,AbCellera Biologics Inc.,ABCL,CIK0001703057,USD,7320000.0,20195000.0,20195000.0,903000.0,36152000.0,27143000.0,5586000.0,,5919000.0,4127000.0,8397000.0,2519000.0,,1005536000.0,813325000.0,192211000.0,,13411000.0,9148000.0,594116000.0,900000.0,594116000.0,586563000.0,269497768.0,269497768.0,710387000.0,118918000.0,26321000.0,6589000.0,3000000.0,4270000.0,4300000.0,2098000.0,26161000.0,2317000.0,4836000.0,0.53,0.45,,1988000.0,,,2520000.0,,,,,,117673000.0,,11910000.0,31500000.0,157833000.0,38915000.0,36412000.0,21810000.0,,-1466000.0,5467000.0,27143000.0,63260090.0,40674652.0,115153000.0,19247000.0,175028000.0,1005536000.0,103490000.0,71538000.0,190000.0,683653000.0,-119780000.0,22690000.0,118918000.0,85101000.0,118918000.0,,9060000.0,1802000.0,77124000.0,156031000.0,675000.0,3715000.0,435000.0,5970000.0,8388000.0,,6620000.0,-4707000.0,-6511000.0,,,87643000.0,19247000.0,5000000.0,,,9673000.0,33817000.0,4073000.0,,15490000.0,74662000.0,,1000000.0,118918000.0,23509000.0,17923000.0,19942000.0,,29393000.0,114202000.0,233155000.0,27143000.0,3842000.0,8397000.0,830508000.0,74662000.0,942000.0,1988000.0,212336000.0,263129765.0,159195023.0,,0.0,22600000.0,,593700000.0,400000.0,0.0,36931000.0,-114000.0,36817000.0,2461000.0,-363000.0,31411000.0,,11915000.0,20263000.0,11148000.0,408000.0,1500000.0,949000.0,767000.0,19496000.0,26300000.0,41000.0,,707000.0,,,0.27,1934000.0,,,-300000.0,31500000.0,,163077000.0,-5244000.0,489000.0,-680000.0,42615000.0,756000.0,1698000.0,293000.0,,,,,,,,,,1100000.0,4390000.0,,675000.0,522840000.0,1783000.0,-387000.0,,780000.0,1035000.0,,109000.0,387000.0,109000.0
2021-03-31,2021-05-14,10-Q,AbCellera Biologics Inc.,ABCL,CIK0001703057,USD,3585000.0,13287000.0,13287000.0,23371000.0,30030000.0,20010000.0,6285000.0,,14562000.0,4021000.0,5427000.0,2465000.0,,1128523000.0,907982000.0,220541000.0,,13762000.0,9378000.0,685795000.0,,685795000.0,91679000.0,270925930.0,270925930.0,711139000.0,,32375000.0,11306000.0,1300000.0,474000.0,500000.0,623000.0,26992000.0,840000.0,3305000.0,0.43,0.37,-484000.0,,,,4985000.0,9860000.0,9860000.0,3476000.0,3476000.0,9834000.0,117673000.0,36506000.0,6422000.0,31500000.0,161487000.0,44266000.0,-6123000.0,6086000.0,,1924000.0,30073000.0,-7134000.0,,50585535.0,112688000.0,32187000.0,171399000.0,1128523000.0,88395000.0,83004000.0,,-1543000.0,-15839000.0,109545000.0,117221000.0,117221000.0,117221000.0,423000.0,,3413000.0,44667000.0,158074000.0,1533000.0,16973000.0,661000.0,5745000.0,9548000.0,,931000.0,191000.0,265000.0,,,,12195000.0,,,,3644000.0,,4287000.0,,,,,173000.0,117221000.0,40903000.0,34618000.0,1716000.0,,12352000.0,231423000.0,202741000.0,20010000.0,2578000.0,5427000.0,957124000.0,,173000.0,1207000.0,193071000.0,320282747.0,269697212.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-06-30,2021-08-13,10-Q,AbCellera Biologics Inc.,ABCL,CIK0001703057,USD,5605000.0,18276000.0,18276000.0,2799000.0,5822000.0,23520000.0,7341000.0,2152000.0,21669000.0,8473000.0,8473000.0,,47221295.0,1151856000.0,864002000.0,287854000.0,,11572000.0,9614000.0,792571000.0,,792571000.0,,276982678.0,276982678.0,714758000.0,-171000.0,31232000.0,10568000.0,1800000.0,,,,25510000.0,1100000.0,3522000.0,-0.01,-0.01,,2346000.0,,,7450000.0,9860000.0,9860000.0,3476000.0,3476000.0,8238000.0,117673000.0,34910000.0,11203000.0,31500000.0,-2073000.0,250000.0,,,,,,,,,110223000.0,42705000.0,184177000.0,1151856000.0,69758000.0,114419000.0,,,,,-2323000.0,-2323000.0,-2323000.0,,,4960000.0,34676000.0,-7033000.0,2220000.0,31020000.0,,6547000.0,15947000.0,2152000.0,1657000.0,,314000.0,,,,,,,,,,4916000.0,,,,,,,94820000.0,87479000.0,,,15046000.0,229100000.0,27643000.0,3610000.0,1295000.0,,967679000.0,,1779000.0,,62085000.0,272196107.0,272196107.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-09-30,2021-11-10,10-Q,AbCellera Biologics Inc.,ABCL,CIK0001703057,USD,8908000.0,24072000.0,24072000.0,,6590000.0,595000.0,8505000.0,644000.0,26945000.0,7707000.0,7707000.0,,44848480.0,1172732000.0,803747000.0,368985000.0,235785000.0,12122000.0,44948000.0,517694000.0,,517694000.0,,281151877.0,281151877.0,718088000.0,-22888000.0,35350000.0,6170000.0,1500000.0,,,,36197000.0,1200000.0,3666000.0,-0.08,-0.08,,3617000.0,0.0,0.0,9952000.0,10305000.0,10305000.0,3921000.0,3921000.0,7087000.0,158773000.0,35539000.0,11271000.0,49457000.0,-24972000.0,-3592000.0,,,,,,,,,148821000.0,47507000.0,219335000.0,1172732000.0,49549000.0,169786000.0,,,,,-21380000.0,-21380000.0,-21380000.0,,,3124000.0,33604000.0,-28096000.0,2800000.0,27264000.0,,6635000.0,31616000.0,-1508000.0,1695000.0,,-1256000.0,,,,,,,,,,,,,,,,,100089000.0,91584000.0,,,17450000.0,207720000.0,5508000.0,0.0,1217000.0,,953397000.0,,899000.0,,,278933760.0,278933760.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-12-31,2022-02-25,10-K,AbCellera Biologics Inc.,ABCL,CIK0001703057,USD,14924000.0,32017000.0,32017000.0,,35683000.0,22506000.0,9826000.0,280000.0,35357000.0,29240000.0,30646000.0,10062000.0,908409.0,1318569000.0,929800000.0,388769000.0,246835000.0,22934000.0,35886000.0,476142000.0,8200000.0,501142000.0,-92974000.0,283257104.0,283257104.0,722430000.0,153744000.0,34954000.0,7536000.0,4700000.0,,,-2018000.0,37370000.0,4403000.0,14451000.0,0.56,0.48,-1425000.0,4035000.0,0.0,0.0,12581000.0,10425000.0,,4041000.0,5610000.0,10425000.0,160973000.0,34542000.0,41848000.0,47806000.0,219149000.0,65685000.0,-13530000.0,8624000.0,,2603000.0,37386000.0,-4637000.0,,42530491.0,148392000.0,50313000.0,292836000.0,1318569000.0,120676000.0,172160000.0,,-3886000.0,-332247000.0,244584000.0,153464000.0,153464000.0,153464000.0,,,14736000.0,170790000.0,204413000.0,3652000.0,36413000.0,2785000.0,21247000.0,30642000.0,280000.0,1733000.0,-3570000.0,-5225000.0,2550000.0,,11457000.0,30323000.0,,,274710000.0,58452000.0,,,,872000.0,,27608000.0,4615000.0,153464000.0,121442000.0,111616000.0,1823000.0,,62062000.0,267666000.0,375203000.0,45516000.0,6913000.0,30646000.0,1025733000.0,,,,,318294236.0,275763745.0,0.0,0.0,,33300000.0,100500000.0,375600000.0,0.0,60498000.0,7248000.0,67746000.0,-1342000.0,-719000.0,51679000.0,4768000.0,30950000.0,29962000.0,21717000.0,4996000.0,18200000.0,3019000.0,9233000.0,20729000.0,36866000.0,1661000.0,2135000.0,3256000.0,0.0,0.0,0.27,7007000.0,0.5,4041000.0,-855000.0,16306000.0,0.0,211471000.0,7678000.0,14282000.0,5007000.0,59170000.0,-738000.0,4809000.0,3330000.0,0.1,19800000.0,22133000.0,4623000.0,4694000.0,4980000.0,5070000.0,4796000.0,246800000.0,4100000.0,40065000.0,0.033,2875000.0,,,,25000000.0,6764000.0,13595000.0,,,109000.0,
